Targovax ASA: First quarter 2022 results
Oslo, Norway, 12 May 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2022 results. Members of Targovax’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).1Q 2022 HIGHLIGHTS Business Development · Announced two key collaboration agreements with Agenus: · Free drug supply of two checkpoint inhibitors for ONCOS-102 combination therapy in the upcoming phase 2 melanoma trial